According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0579-0036. The time required to complete this information collection is estimated to average .5 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

OMB APPROVED
0579-0036

Interagency Report Control No. 0180-DOA-AN

Fiscal year: 2022

UNITED STATES DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE

Annual Report of Research Facility
Column E Explanation

(TYPE OR PRINT)

This information is required by law (7 U.S.C. 2143 and 9 C.F.R. §2.36). Failure to report according to the regulations can result in an order to cease and desist.

1. REGISTRATION NUMBER

43-V-0001

2. Research Facility Headquarters address

HARRY S. TRUMAN VAMC(543)
800 HOSPITAL DRIVE
COLUMBIA, MO 65201
Telephone: 5738146550

3. Number of animals used in the study.

30 (rabbit)

4. Species (common name) of animals used in the study.

rabbit

5. Explain the procedure producing pain and distress.

Occular Alkali (sodium hydroxide) or gaseous agent exposure (acrolein/chlorine/hydrogen sulphide)

6. Provide the scientific justification for not providing the appropriate anesthetics, analgesics, or tranquilizing drugs during procedures where the animal experienced accompanying pain or distress greater than momentary or slight.

From the ACORP text as approved by the VA SAS IACUC and as part of the PI's VA BLR&D Merit funded work:
Alkali (sodium hydroxide) or gaseous agent exposure (acrolein/chlorine/hydrogen sulphide) We propose to withhold pain/distress-relieving drugs as they may hinder the wound healing process and will hinder interpretations of effects from our therapies. Both topical anesthetics/analgesics (like proparacaine, NSAIDS) (reference 1) and opioid analogues (like buprenorphine, morphine, etc) (reference 2, reference 3) have been shown to alter the wound healing process in cornea. These drugs interfere with the same intercellular signaling pathways which we propose to modify with our therapies. In fact, topical proparacaine as pain reliever has been shown to delay corneal wound healing (reference 1).

References:

7. What, if any, Federal regulations require this procedure? Cite the agency, the Code of Federal Regulations (CFR) title number, and the specific section number (e.g., APHIS, 9 CFR 113, 102):

Agency	CFR

Obtained by Rise for Animals.
Uploaded to Animal Research Laboratory Overview (ARLO) on 08/24/2023